The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Urology

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2008.10.037PMID 19013011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

  2008influential reference
• Do α1‐adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?

  2008cited by this paper
• Statistics in medicine--reporting of subgroup analyses in clinical trials.

  2007cited by this paper
• Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.

  2007cited by this paper
• Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.

  2006influential reference
• Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function

  2005cited by this paper
• EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

  2004cited by this paper
• AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

  2003cited by this paper
• Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.

  2003cited by this paper
• The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

  2003cited by this paper
• Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

  2003cited by this paper
• Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

  2003cited by this paper
• Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia

  1998cited by this paper
• The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

  1996cited by this paper

• Alterations and ameliorative effects of methanolic extract of Chromolaena odorata on some hematology and serum biochemistry parameters in rats induced with experimental benign prostatic hyperplasia

  2025cites this paper
• MXene/PEDOT:PSS-based dual-biomarker impedimetric immunosensor for accurate differentiation of prostate cancer from BPH through urinary detection.

  2025cites this paper
• Exploring pharmacological interventions in benign prostate hyperplasia: the role of cost-effectiveness analysis in daily practice and future directions

  2024cites this paper
• Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia.

  2024cites this paper
• Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders

  2023cites this paper
• Global Incidence and Risk Factors Associated With Postoperative Urinary Retention Following Elective Inguinal Hernia Repair: The Retention of Urine After Inguinal Hernia Elective Repair (RETAINER I) Study.

  2023cites this paper
• Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression

  2023cites this paper
• Efficacy of surgical treatment for post-prostatectomy urinary incontinence: a systematic review and network meta-analysis

  2023cites this paper
• Can prophylactic tamsulosin reduce the risk of urinary retention after surgery? A systematic review and meta-analysis of randomized control trials

  2023cites this paper
• Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy.

  2022cites this paper
• Lower urinary tract symptoms (LUTS): The role of medications in improvement of quality of life

  2022cites this paper
• Impact of preoperative 5-alpha reductase inhibitor treatment in holmium laser enucleation of the prostate

  2022cites this paper
• Prophylactic tamsulosin can reduce the risk of urinary retention after surgery in male patients: A systematic review and meta-analysis

  2022cites this paper
• Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis

  2021influential citation
• Preliminary results of a randomized crossover clinical trial comparing a new electromagnetic and vibrating device and alpha-blocker agents in patients affected by bladder outlet obstruction secondary to benign prostatic hyperplasia.

  2021cites this paper
• Management of Non-Neurogenic Male Lower Urinary Tract Symptoms ( LUTS ) , incl . Benign Prostatic Obstruction ( BPO ) EAU Guidelines on

  2021cites this paper
• GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.

  2021cites this paper
• Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross‐sectional study

  2021cites this paper
• Benign Prostatic Obstruction ( BPO ) EAU Guidelines on

  2020cites this paper
• High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5 Alpha-Reductase Inhibitors for Benign Prostatic Hyperplasia.

  2020cites this paper
• Functional Evaluation of Upper Urinary Tract with Diuretic Mercaptoacetyltriglycine Renal Scans in Patients with Benign Prostatic Obstruction before and after Surgical Intervention: A Pilot Study

  2020cites this paper
• Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study

  2020cites this paper
• Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

  2020cites this paper
• Physiology and Pharmacology of the Prostate

  2020cites this paper
• Benign Prostate Hyperplasia

  2020cites this paper
• Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group

  2019cites this paper
• Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open‐label, non‐inferiority trial

  2019cites this paper
• Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction

  2019cites this paper
• Neurourology and Urodynamics

  2019cites this paper
• Transurethral prostate surgery as a preventive method against progression of chronic kidney disease in patients with urodynamically proven bladder outlet obstruction

  2019cites this paper
• Benign prostate hyperplasia and nutrition.

  2019cites this paper
• BPO/LUTS – Aktuelles zur medikamentösen Therapie

  2019cites this paper
• The relation between baseline PSA and symptomatic progression in Egyptian BPH patients receiving tamsulosin monotherapy: an exploratory multicentric prospective study

  2019cites this paper
• Effect of stachydrine hydrochloride to the prostate hyperplasia model in mice

  2018cites this paper
• Urologists’ attitudes to sexual complications of LUTS/BPH treatments

  2018cites this paper
• Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data

  2018cites this paper
• Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics

  2018cites this paper
• Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia.

  2018cites this paper
• The Benign Prostatic Hyperplasia and Its Aetiologies

  2018cites this paper
• Effect of Aqueous Extract of Vernonia amygdalina on Biochemical Indices of Prostate Functions in Hormonal Induced Enlarged Prostate in Rats

  2018cites this paper
• Investigating the Binding-Targets of the Aqueous Root Extract of Croton Membranaceous in Hyperplastic Prostate Tissue.

  2018influential citation
• Benigna hiperplazija prostate – medikamentozno liječenje Benign prostatic hyperplasia – medicamentous treatment

  2017cites this paper
• Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression

  2017cites this paper
• Benigna hiperplazija prostate - medikamentozno liječenje

  2017cites this paper
• Systematic Review in Patients with Benign Prostatic Hyperplasia for The Role of Prostatic Arterial Embolization

  2017cites this paper
• Rice Hull Extract Suppresses Benign Prostate Hyperplasia by Decreasing Inflammation and Regulating Cell Proliferation in Rats

  2016cites this paper
• Role of homoeopathic medicines in prostate enlargement: A retrospective observational study

  2016cites this paper
• Korean clinical practice guideline for benign prostatic hyperplasia

  2016cites this paper
• [Urological Diseases in Men and their Prevention].

  2016cites this paper
• [Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].

  2016influential citation
• Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia

  2016cites this paper
• 5-Alpha-Reductase Inhibitors and Combination Therapy.

  2016cites this paper
• Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.

  2016cites this paper
• 25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World

  2016cites this paper
• Benign prostatic hyperplasia and prostate-specific antigen.

  2015cites this paper
• Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)

  2015cites this paper
• 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.

  2015cites this paper
• Body mass index and age are predictors for symptom improvement after high-power laser vaporization for benign prostatic hyperplasia.

  2015cites this paper
• A hybrid fuzzy-ontology based intelligent system to determine level of severity and treatment recommendation for Benign Prostatic Hyperplasia

  2014cites this paper
• Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4‐year results of the CombAT study

  2014cites this paper
• Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

  2014cites this paper
• Does Baseline Prostate Volume Affect the Short‐Term Outcome of Tamsulosin?

  2014cites this paper
• α-Spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model.

  2014cites this paper
• Differential gene expression analysis and genetic association studies in benign and malignant prostate tissues

  2014cites this paper
• Non-neurogenic Male Lower Urinary Tract Symptoms (incl. Benign Prostatic Hyperplasia)

  2014cites this paper
• Complementary and Alternative Medicine Interventions for BPH/LUTS

  2014cites this paper
• Combination Medical Therapy for Male Lower Urinary Tract Symptoms

  2014cites this paper
• Machen Sie aus dem Träufeln wieder einen Fluss!

  2014cites this paper
• Could We Reach the Standard Treatment of Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia?

  2014cites this paper
• Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.

  2014cites this paper
• How much improvement is needed for a real difference of lower urinary tract symptoms after long‐term combination therapy for benign prostatic hyperplasia

  2014cites this paper
• [Lower urinary tract symptoms associated with benign prostatic enlargement].

  2014cites this paper
• Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP‐1 transcription factor network

  2014cites this paper
• Medical Management of Lower Urinary Tract Symptoms in Men with Benign Prostatic Enlargement

  2013cites this paper
• Les médicaments de l'urètre

  2013cites this paper
• [Drug therapy of urethral diseases].

  2013cites this paper
• The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study

  2013cites this paper
• Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia

  2013cites this paper
• Dutasteride/tamsulosin: a guide to its use in benign prostatic hyperplasia

  2013cites this paper
• α1‐blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5‐year outcome analysis of a prospective multicenter study

  2013cites this paper
• Systematic review evaluating cardiovascular events of the 5‐alpha reductase inhibitor – Dutasteride

  2013cites this paper
• Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

  2013cites this paper
• Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

  2013cites this paper
• A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

  2012cites this paper
• An overview of prostate diseases and their characteristics specific to Asian men.

  2012cites this paper
• 3D-QSAR CoMFA and CoMSIA studies for design of potent human steroid 5α-reductase inhibitors

  2012cites this paper
• Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study

  2012cites this paper
• Benign prostatic hyperplasia (BPH) management in the primary care setting.

  2012cites this paper
• 09 : 50 10 : 05 Is it possible to preserve bladder function ?

  2012cites this paper
• 131 – Benign Prostatic Hyperplasia and Prostatitis

  2012cites this paper
• An evidence based case study of benign prostatic hyperplasia

  2012cites this paper
• – Benign Prostatic Hyperplasia A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with a-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

  2012cites this paper
• Dutasteride/Tamsulosin

  2012influential citation
• Pathology and Medical Therapy of Benign Prostatic Hyperplasia

  2011cites this paper
• A multiinstitutional study of the effects of medical therapy for lower urinary symptoms on the perioperative outcomes of holmium laser enucleation of the prostate.

  2011cites this paper
• Tm:YAG laser vapoenucleation (ThuVEP) – One-year follow-up in elderly patients

  2011cites this paper
• LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

  2011cites this paper
• Annual drug update: 2010 in review.

  2011cites this paper
• Voiding parameters and prostate size in prostate cancer patients undergoing long term endocrine manipulation

  2011cites this paper
• Increased risk of benign prostatic enlargement among patients with liver cirrhosis: a nationwide population-based study.

  2011cites this paper